Sesamol suppresses cyclooxygenase-2 transcriotional activity in colon cancer cells and modifies intestinal polyp development in ApcMin/+ mice

Satomi Shimizu,1,2 Gen Fujiy,1 Mami Takahashi,1 Ruri Nakanishi,1 Masami Komiya,1 Misato Shimura,1,4 Nobuharu Noma,1,4 Wakana Onuma,1,4 Masaru Terasaki,2 Tomohiro Yano2 and Michihiro Mutoh1,*

1Division of Cancer Prevention Research and 2Central Animal Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Faculty of Life Sciences, Toyo University, 1-1-1 Izumino, Itakura-machi, Ogagun, Gunma 374-0193, Japan
3School of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan
4Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan

(Received 11 October, 2013; Accepted 4 December, 2013; Published online 19 February, 2014)

Excessive prostaglandin production by cyclooxygenase-2 in stromal and epithelial cells is a causative factor of colorectal cancerogenesis. Thus, compounds which inhibit cyclooxygenase-2 transcriptional activity in colon epithelial cells could be candidates for anti-cancerogenic agents. A cyclooxygenase-2 transcriptional activity in the human colon cancer cell line DLD-1 has been measured using a β-galactosidase reporter gene system. Using this system, we demonstrated that the decrease in basal cyclooxygenase-2 transcriptional activities at 100 μM sesamol, one of the lignans in sesame seeds, was 50%. Other compounds in sesame seeds such as sesamin, sesaminol, ferulic acid, and syringic acid did not exhibit significant suppression of cyclooxygenase-2 transcriptional activity at up to 100 μM. In a following experiment, 6-week-old male Min mice, Apc-deficient mice, were divided into a non-treated and 500 ppm sesamol groups. At the age of 15 weeks, it was found that treatment with sesamol decreased the number of polyps in the middle part of small intestine to 66.1% of the untreated value. Moreover, sesamol reduced cyclooxygenase-2 and cytosolic prostaglandin E2 synthase mRNA in the polyp parts. The present findings may demonstrate the novel anti-carcinogenetic property of sesamol, and imply that agents that can suppress cyclooxygenase-2 expression may be useful cancer chemopreventive agents.

Key Words: cyclooxygenase-2, reporter gene assay, sesame, sesamol, Min mice

The sesame plant (Sesamum indicum, Linn.) is well known for its edible seeds and oil.1 Sesame seeds are characterized by the presence of fatty acids (linoleic acid, linolenic acid, oleic acid, palmitic acid and stearic acid), oil-soluble lignans (episesamin, sesaminol, sesaminol, and sesamolin) and other phenol compounds (γ-tocopherol, ferulic acid and syringic acid). The nonfat portion of sesame seed is only 1–2% by wet weight. Recently, multiple biological functions of sesame seeds, such as inhibition of inflammation and carcinogenesis, have been elucidated. In experimental studies, sesamol was shown to inhibit development of spontaneous development of preneoplastic hepatoctytic foci in rats.2 Sesamin reduced the incidence of chemically induced rat mammary gland cancers.3 Moreover, sesame oil has been reported to inhibit growth of human colon cancer cells in vitro.4 These effects of sesame seed and its constituents were partly associated with its hydroxyl radical scavenging activity, inhibitory activity of lipid peroxidation and anti-mutagenic activity.5–7 However, the desirable biological functions have not entirely been elucidated yet.

Recent accumulating evidence has indicated that prostaglandins (PGs) are implicated in colon carcinogenesis.6 Expression levels of cyclooxygenase-2 (COX-2) are increased in colon carcinoma tissues compared to that of normal colonic mucosa. Therefore, inhibitors against COX-2 have been studied extensively for their ability to suppress colon carcinogenesis. It has been also reported that COX-2 gene knockout causes significant reduction in number and size of intestinal polyps in a mouse model for human familial adenomatous polyposis. Apc-deficient Min mice.8 Thus, it is likely that agents that can suppress COX-2 expression at the transcriptional level may be equally advantageous.

As reported in previous papers,9–12 we have constructed a β-galactosidase reporter gene system to test the effects of compounds on COX-2 transcriptional activity in a human colon cancer cell line, DLD-1 cells. In the present study, effects of five sesame seeds constituents on the transcriptional activity of COX-2 were investigated and one constituent, sesamol, was found to suppress basal COX-2 transcriptional activity. In a further experiment, we investigated the suppressive effect of sesame on intestinal polyp development and on COX-2 expression levels in Min mice.

Materials and Methods

Chemicals. Sesamin were obtained from Cayman Chemical, (Ann Arbor, MI), ferulic acid, sesamol and syringic acid were from Sigma-Aldrich Co. (St. Louis, MO). Sesaminol was from Nagara, Ltd. (Gifu, Japan).

Cell culture. DLD-1 cells, a human colon adenocarcinoma cell line, were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). Construction of DLD-1/COX-2-B2-βGal-BSD cells has been reported in our previous papers.13 The cells were maintained in DMEM medium supplemented with 5% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories Inc., Logan, UT) and antibiotics (100 μg/ml streptomycin and 100 U/ml penicillin) at 37°C in 5% CO2.

Measurements of cell viability. Cell viability in each culture was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells at a density of 2.0 × 104 cells per well were seeded in 96-well tissue culture plates
and treated with sesame constituents for 48 h. After treatment, the cells were further incubated in a medium containing 0.5 mg/mL of MTT for 1 h. The MTT formazan produced by living cells was dissolved in dimethyl sulfoxide and absorbance at 595 nm was measured on a microplate Reader (Bio-Rad Laboratories, CA).

**Reporter gene assay for COX-2 promoter-dependent transcriptional activity.** DLD-1/COX-2-B2-βGal-BSD cells were seeded at a density of 2.0 × 10^4 cells per 96-well tissue culture plate and precultured for 24 h. After treatment with the test reagents, the total β-galactosidase activities of the cells in each well were determined by colorimetric assay using o-nitrophenyl-β-d-galactopyranoside (ONPG) as described previously. The background β-galactosidase activity of DLD-1 cells was determined in non-treated DLD-1/B2-βGal-BSD cells, and the value was set as 0. Basal β-galactosidase activity of non-treated DLD-1/COX-2-B2-βGal-BSD cells was set as 100%. The percent β-galactosidase activity of each treatment was calculated from triplicate wells. The viable cell number was assessed by the MTT assay. All assays, including MTT assay, were carried out in triplicate and each experiment repeated at least three times.

**Quantitative real-time polymerase chain reaction (PCR) analysis.** Total RNA was isolated using TRIzol Reagent (Invitrogen, NY), treated with DNase (Invitrogen, Grand Island, NY) and 1 μg aliquots in a final volume of 20 μL were used for synthesis of cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR was carried out using Fast Start Universal SYBR Green Mix (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. Primers for COX-1 (5'-TGA TGC TCT TCT CCA CGA and 5'-GCA GGA AAT AGC CAC TCA AG), COX-2 (5'-GTG CCA ATT GCT GTA CAA GC and 5'-TAC AGC TCA GTT GAA CGC CT), cPGES (5'-AGT CAT GGC CTA GGT TAA C and 5'-ATT GCT GTA CAA GC), EP2 (5'-AGG ACT TGT GAA TCA TCA TCT GCT CC), EP1 (5'-ACC CTG CAT CGC CT), cPGES (5'-TGT CAG CAA GTA TGG GTC AG), mPGES-2 (5'-AAT GCT and 5'-GCC GCT GTG CCG GGA), EP2 (5'-AGG ACT TGT GCA GAG AC and 5'-CAG CCC CTT ACA CTT CTC CAA TG), EP3 (5'-TGA CCT TTG CTT GCA ACC TTG and 5'-AGA CAA TGA GAT GGC CTG CC), EP4 (5'-TGC CTC TGG TGC GAG TGT TC and 5'-GAG GTG GTG TCT GCT GTC AG), mPGES-2 (5'-AAG ACA TGT CCC TTC TGC and 5'-CCA AGA TGG CCA GCT GCC CAT TGC at a density of 2 × 10^4/well in 24-well plates, and incubated with 50 and 100 μM sesamol for 24 and 48 h. After treatment, cells were lysed in 100 μl lysis buffer [0.0625 M Tris–HCl (pH 6.8), 20% 2-mercaptoethanol, 10% glycerol, 5% sodium dodecyl sulfate]. Samples were separated in 10% polyacrylamide gel electrophoresis–sodium dodecyl sulfate gels and transferred onto polyvinylidene difluoride membranes (Millipore, MA). Abs against the EP1, EP2, EP4 (Cayman Chemical Co. Ann Arbor, MI) and EP3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used at a 1:2,000 dilution. Peroxidase-conjugated secondary Abs for anti-rabbit IgG were obtained from GE Healthcare (Buckinghamshire, UK). Blots were developed with ECL western blotting detection reagents (GE Healthcare).

**Animals.** Female C57BL/6-ApcMin/+ mice (Min mice) were purchased from The Jackson Laboratory (ME). Mice were housed per plastic cage with sterilized softwood chips as bedding in a barrier-sustained animal room at 24 ± 2°C and 55% humidity on a 12 h light/dark cycle. Sesamol was well mixed at a concentration of 500 ppm in AIN-76A powdered basal diet (CLEA Japan, Tokyo, Japan).

**Protocol for Animal experiments.** Ten female Min mice at 5 weeks of age were given 500 ppm sesamol, for 8 weeks. The animals in each cage were all in the same treatment group. Food and water were available ad libitum. The animals were observed daily for clinical signs and mortality. Body weights and food consumption were measured weekly. The intestinal tract was removed and separated into the small intestine, cecum and colon. The small intestine was divided into the proximal (middle) and distal halves of the remainder. Polyps in the proximal segments were counted and all

---

**Fig. 1.** Chemical structures of the five constituents in the sesame seed. (A), sesamol; (B), sesamin; (C), sesamolin; (D), ferulic acid; (E), syringic acid.
polyps in the proximal segment were picked up under a stereoscopic microscope and the remaining intestinal mucosa (non-polyp part) was removed by scraping, and then both stored at −80°C for further analysis. Other segments were opened longitudinally and fixed flat between sheets of filter paper in 10% buffered formalin. The numbers and sizes of polyps and their distributions in the intestine were assessed with a stereoscopic microscope. The experiments were performed according to the “Guidelines for Animal Experiments in the National Cancer Center” and were approved by the Institutional Ethics Review Committee for Animal Experimentation in the National Cancer Center.

**Statistical analysis.** All the results are expressed as mean ± SD values, with statistical analysis using the Student’s t test, except for the COX-2 promoter activity investigation and mRNA examination in the human cell line. The Bonferroni z test was used for statistical analyses of the COX-2 promoter activity and of human mRNA levels. Differences were considered to be statistically significant at p<0.05.

**Results**

**Suppression of COX-2 promoter activity in human colon cancer cells by sesamol.** Five compounds, shown in Fig. 1, were tested at various concentrations up to 100 μM with regard to their effects on COX-2 promoter activity. Remarkable suppression of cell proliferation rates by five compounds was not observed at the concentrations up to 100 μM in MTT assay. Among five constituents in the sesame seed, only sesamol significantly suppressed COX-2 promoter activity in a dose-dependent manner. Decrease in COX-2 promoter activities by sesamol at 100 μM was 50% (Fig. 2A). The other four compounds, ferulic acid, sesamin, sesamolin, syringic acid exhibited weak or no suppression of COX-2 promoter activity (Fig. 2B–E).

**Suppression of intestinal polyp formation in Min mice by sesamol.** Administration of 500 ppm sesamol to Min mice for 8 weeks did not affect body weights, food intake or clinical signs throughout the experimental period. Average daily food intake did not significantly differ among the groups, being 3.9 and 3.5 g per mouse per day for the 0 and 500 ppm group of Min mice, respectively. In addition, there were no changes observed in any organ weights that might have been attributable to toxicity.

Table 1 summarizes data for the number and distribution of intestinal polyps in the basal diet and sesamol-treated groups. Almost all polyps developed in the small intestine, with only a few in the colon. The total number of polyps tended to be decreased by administration of 500 ppm sesamol to 75% of the untreated control value. Reduction of polyps was observed in the middle part, and was by 66% (p<0.05 vs 0 ppm). In the other parts of small intestine and colon, treatment with sesamol lowered the number of polyps without significant difference.

Fig. 3 shows the size distribution of intestinal polyps in the basal diet and sesamol-treated groups. The maximal number of polyps was observed in the size range between 0.5 and 2.0 mm in diameter. Administration of sesamol significantly reduced the numbers of polyps sized <0.5 mm in diameter.

**Decrease of inflammation-related factors mRNA levels in intestinal polyp parts by sesamol.** Inflammation-related factors mRNA expressions in intestinal polyp parts and non-polyp parts were investigated (Fig. 4). Real-time PCR revealed that treatment with 500 ppm sesamol for 8 weeks significantly suppressed COX-2, and cPGES, mRNA levels in the intestinal polyp parts to 48% (p<0.01) and 54% (p<0.05) of sample value, respec-
clearly detected (data not shown). We further confirmed the EP1–

However, mRNA levels for EP4 were increased and EP3 was not

and EP2 mRNA levels in a dose-dependent manner (Fig. 5).

100

4 protein expression levels in the cells with or without sesamol

COX-2 transcriptional activity,

compounds such as resorcinol and resacetophenone suppress

DLD-1 cells. Previously, we have reported that mono-benzonic

transcriptional activity of the COX-2 gene in human colon cancer

dimensions: 612.0x791.0

Fig. 3. Effects of sesamol on the size distribution of intestinal polyps

in Min mice. Min mice were fed a basal diet (open box) or a containing

500 ppm (black filled box) sesamol for 8 weeks. The number of polyps

per mouse in each size class is given as a mean ± SD. *p<0.05.

Fig. 3. Effects of sesamol on the size distribution of intestinal polyps

in Min mice. Min mice were fed a basal diet (open box) or a containing

500 ppm (black filled box) sesamol for 8 weeks. The number of polyps

per mouse in each size class is given as a mean ± SD. *p<0.05.

tively. mPGES2, EP1 and EP2 mRNA levels tended to be reduced

in intestinal polyp parts by sesamol. COX-1 and EP4 mRNA

expression levels in non-polyp parts and polyp parts of small

intestine were not suppressed by sesamol treatment. Only EP3 did

not increase its expression levels in the intestinal polyp parts

compared to those of mucosa parts, and rather decreased its

expression by sesamol treatment in the intestinal polyp parts.

Decrease of prostaglandin E₂ receptor expression levels

in human colon cancer cells by sesamol. To clarify the

effects of sesamol on EP1 and EP2 mRNA levels in human

cells, we treated DLD-1/COX-2-B2-β-gal-BSB cells with 50 and

100 μM sesamol for 48 h. Sesamol significantly suppressed EP1

and EP2 mRNA levels in a dose-dependent manner (Fig. 5).

However, mRNA levels for EP4 were increased and EP3 was not

clearly detected (data not shown). We further confirmed the EP1–

4 protein expression levels in the cells with or without sesamol

treatment. As shown in Fig. 5D, sesamol down-regulated EP1 and

EP2 protein levels in dose- and time-dependent manner. As in the

case of EP4, sesamol treatment for 24 h slightly increased its

protein levels, whereas 48 h treatment decreased EP4 protein

levels. EP3 expression levels seem to be very low in these cells, as

shown in Fig. 5D.

Discussion

In the present study, sesamol was found to suppress basal

transcriptional activity of the COX-2 gene in human colon cancer

DLD-1 cells. Previously, we have reported that mono-benzonic

compounds such as resorcinol and resacetophenone suppress

COX-2 transcriptional activity([10,11]) but their inhibitory activities

are almost 5-times less than that of sesamol. Thus, sesamol may

have a notable potential to suppress COX-2 expression for a

natural compound.

The underlying mechanism of suppression of COX-2 transcriptional

activity by sesamol is not clear. Protein-tyrosine kinases (PTKs), including the epidermal growth factor receptor, are well

known to be involved in the induction of COX-2 expression([14,15])

Signals from activated PTKs are transduced to the downstream

transcription factor NF-κB, mainly by the Ras and mitogen-activated

protein kinase pathways. It is also known that activation of NF-κB has been reported to play an important role in the regula-

tion of COX-2 expression. However, our preliminary experi-

ment that aimed to evaluate the effects of sesamol on NF-κB

transcriptional activity failed to show its reduction at concentra-

tions up to 100 μM in human colon cancer cells (data not shown).

Further studies are needed to elucidate the molecular mechanisms

responsible for the inhibition of COX-2 transcriptional activity by

sesamol.

We next aimed to show the suppressive potential of sesamol on

intestinal polyp development in Min mice. Administration of

500 ppm sesamol tended to reduce the total number of intestinal

polyps development compared to that of the untreated group.

Further analysis revealed that treatment with sesamol decreased

the number of polyps in the middle part of the small intestine. It

has been reported that indomethacin, a COX inhibitor, and nime-
sulide, a COX-2 selective inhibitor, mainly reduce the number

of polyps in the middle to distal part of the small intestine([16,17])

Thus, sesamol with a COX-2 suppressive function has a similar inhibi-
tory potential for polyp development. For instance, LPL inducers

such as NO-1886 or PPAR ligands effectively reduce the number

of polyps in the proximal part of the small intestine([18,19])

In the polyp parts of Min mice, it was confirmed that sesamol

could suppress expression levels of COX-2 mRNA. In addition,
cPGES mRNA was reduced by sesamol treatment, and this is the

first report that suggests suppressive effects of sesamol on cPGES

as far as we know. Moreover, a tendency to suppression was

observed in the expression levels of PGE₂ receptor subtypes EP1

and EP2 in the polyp parts of Min mice. Using PGE₂ receptor

subtype-knockout mice, the roles of these receptors in colon

carcinogenesis have been investigated([20-23]) These observations

suggest that EP1, EP2 and EP4 are promotive receptors in

colorectal carcinogenesis, and EP3 plays suppressive roles. EP1

signals transmitted by increased intracellular Ca²⁺ concentrations

activate protein kinase C (PKC). However, the actual signal

transduction mechanisms are not known in detail([24,25]) Stimulation

of EP2 and EP4 receptors in both cases involves coupling with

stimulatory G protein, leading to activation of adenylyc cyclase.

As a result, increased cAMP levels activate cAMP-dependent

protein kinase (PKA) and increase a transcriptional factor that

bids to CAMP-responsive element, that plays a role in cell growth

and cell survival. Thus, it may be worthwhile to develop func-
tional inhibitors or specific suppressors for EP1, EP2 and EP4.

However, it is regrettable that there are a few inhibitors for PGE₂

receptor subtypes. To add to the novel potential of sesamol, we

confirmed the effect of sesamol on human EP1 and EP2 mRNA

levels. We found suppression of EP1 and EP2 mRNA levels by

sesamol treatment. Down-regulation of EP1 and EP2 protein was

also confirmed. These data imply a double suppressive potential

exists in sesamol regarding cell growth function of PGE₂. Sup-
pression of COX-2 may reduce production of growth lipid

mediator PGE₂, and down regulation of PGE₂ receptors such as

Table 1. Number of intestinal polyps/mouse in Min mice

<table>
<thead>
<tr>
<th>Sesamol (ppm)</th>
<th>No. of mice</th>
<th>Small intestine</th>
<th>Colon</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Proximal</td>
<td>Middle</td>
<td>Distal</td>
</tr>
<tr>
<td>0</td>
<td>9</td>
<td>4.9±4.6</td>
<td>17.1±5.6</td>
<td>22.1±11.7</td>
</tr>
<tr>
<td>500</td>
<td>8</td>
<td>2.4±1.5</td>
<td>11.3±5.6*</td>
<td>19.9±4.4</td>
</tr>
</tbody>
</table>

Data are mean ± SD. *Significantly different from the control untreated group at p<0.01. *p = 0.087.
EP1 and EP2 may additionally suppress tumor growth through a transmembrane G protein-coupled receptor.

In summary, sesamol suppressed the transcriptional activity of COX-2 gene in DLD-1 cells. Moreover, our in vivo data imply that agents that can suppress COX-2 expression at the gene level may be useful cancer chemopreventive agents. Further information of the mechanisms by which sesamol suppresses COX-2 expression may clarify the anti-inflammatory and anti-carcinogenic properties of sesamol.

Fig. 4. Changes of inflammation-related factors in intestinal non-polyp mucosa parts and/or polyp parts of Min mice. Quantitative real-time PCR analysis were performed to determine COX-1 (A), COX-2 (B), cPGES (C), mPGES2 (D), EP1 (E), EP2 (F), EP3 (G), EP4 (H) mRNA expression levels in the polyps or non-polyp mucosa parts of Min mice, given diets containing sesamol at doses of 500 ppm for 8 weeks. Data are normalized with GAPDH expression level. Data are mean ± SD, n = 6. **p<0.01, *p<0.05 vs 0 ppm.

**Acknowledgments**

This work was supported by Grants-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour, and Welfare of Japan, and also from Grants-in-Aid for Project Future, Relay for Life (Japan Cancer Society), and also supported by the National Cancer Center Research Core Facility.

**Abbreviations**

cPGES  cytosolic PGES  
COX  cyclooxygenase  
FBS  fetal bovine serum  
mPGES  microsomal PGES  
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NF-κB  nuclear factor-κB  
ONPG  o-nitrophenyl-β-D-galactopyranoside  
PGs  prostaglandins  
PGES  prostaglandin E synthase  
PTKs  protein-tyrosine kinases
Conflict of Interest

No potential conflicts of interest were disclosed.

References

16 Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in...


